Kedokteran & Kesehatan editorial
Open AccessOA2022
The Difficulty in Translating the Preclinical Success of Combined TGFβ and Immune Checkpoint Inhibition to Clinical Trial
Despite near-uniform preclinical success, combining TGFβ inhibitors with immune checkpoint inhibitors has largely failed to show meaningful clinical benefit. This review summarizes landmark clinical studies and calls for mechanism-driven strategies and predictive biomarkers.
Anastasia E. Metropulos; H. Munshi; D. Principe· EBioMedicine· 2022· DOI 10.1016/j.ebiom.2022.104380
The core problem
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of solid tumors, but responses vary widely even among cancers considered ICI-sensitive. There is a pressing need to identify novel strategies to improve therapeutic responses, both for cancers where ICIs are already indicated and for those where they have yet to show significant activity. Transforming Growth Factor β (TGFβ) signaling has emerged as a critical barrier to ICI efficacy. Preclinical studies have consistently shown that combining TGFβ inhibition with immune checkpoint blockade yields synergistic anti-tumor effects across a wide range of tumor types. This has generated considerable enthusiasm for translating this approach to the clinic. However, as these combinations enter clinical trials, the addition of TGFβ inhibitors has often failed to provide meaningful benefit beyond ICIs alone. This review summarizes landmark clinical studies exploring combined TGFβ and immune checkpoint blockade, highlighting the challenges of translating preclinical success to clinical benefit and underscoring the need to re-evaluate trial design.
Innovation
This review synthesizes findings from landmark clinical trials that have evaluated the combination of TGFβ inhibitors with immune checkpoint inhibitors. The authors systematically examine published clinical studies, focusing on those that have reported outcomes for this combination strategy. The review encompasses trials across various solid tumor types, including those known to be sensitive to ICIs as well as those with limited responsiveness. The methodology involves a critical appraisal of trial designs, patient populations, combination strategies, and reported clinical outcomes. By comparing preclinical evidence with clinical results, the authors identify key discrepancies and propose potential explanations for the lack of translation. The review also discusses the limitations of current trial designs and the need for improved biomarkers to guide patient selection and combination strategies.
Introduction
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of solid tumors, but responses vary widely even among cancers considered ICI-sensitive. There is a pressing need to identify novel strategies to improve therapeutic responses, both for cancers where ICIs are already indicated and for those where they have yet to show significant activity. Transforming Growth Factor β (TGFβ) signaling has emerged as a critical barrier to ICI efficacy. Preclinical studies have consistently shown that combining TGFβ inhibition with immune checkpoint blockade yields synergistic anti-tumor effects across a wide range of tumor types. This has generated considerable enthusiasm for translating this approach to the clinic. However, as these combinations enter clinical trials, the addition of TGFβ inhibitors has often failed to provide meaningful benefit beyond ICIs alone. This review summarizes landmark clinical studies exploring combined TGFβ and immune checkpoint blockade, highlighting the challenges of translating preclinical success to clinical benefit and underscoring the need to re-evaluate trial design.
Why it matters
The discrepancy between preclinical and clinical results raises important questions about the design of trials testing TGFβ and immune checkpoint blockade. Several factors may contribute to the lack of translation. First, preclinical models often do not accurately reflect the heterogeneity and immune complexity of human tumors. Second, the timing, dosing, and sequence of combination therapy may be suboptimal in clinical trials. Third, patient selection has been largely unguided, without biomarkers to identify those most likely to benefit from TGFβ inhibition. The authors argue that future trials should incorporate mechanism-driven combination strategies, such as dual blockade of TGFβ and immune checkpoints with careful consideration of the tumor immune contexture. Additionally, the development of predictive biomarkers is essential to identify patients whose tumors are dependent on TGFβ signaling and who might therefore respond to combination therapy. The review calls for a re-evaluation of trial design, emphasizing the need for translational studies that bridge preclinical and clinical findings, and for adaptive trial designs that allow for refinement based on emerging data. Ultimately, overcoming the barriers to translating TGFβ combination therapy will require a deeper understanding of the biology and a more personalized approach to treatment.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member content…